Opportunity Information: Apply for RFA AI 13 059
Apply for RFA AI 13 059
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Prevention Innovation Program (PIP) (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Feb 20, 2014 and posted on Feb 20, 2014.
- Applicants must submit their applications by Jul 10, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,400,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $400,000.00 in funding.
- Eligible applicants include: Independent school districts County governments Native American tribal governments (Federally recognized) Special district governments State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Public housing authorities/Indian housing authorities City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education Small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Prevention Innovation Program (PIP) (R01) is a National Institutes of Health (NIH) funding opportunity designed to push forward non-vaccine biomedical prevention (nBP) research aimed at reducing or stopping HIV acquisition and transmission. The program is positioned specifically to strengthen and sustain the long-term pipeline of HIV prevention options by encouraging projects that are high-risk and highly innovative, meaning proposals can pursue newer concepts, less-tested approaches, or underexplored candidates that may not yet have extensive supporting data but could meaningfully advance the field if successful. The mechanism is an NIH Research Project Grant (R01), which generally supports hypothesis-driven or milestone-driven research and development efforts with enough scope to move a prevention concept forward through key stages of discovery and early development.
A major emphasis of PIP is on discovering and developing novel or underexplored nBP candidates and strategies. In practical terms, this includes work on new prevention agents, formulations, or biological approaches that are not vaccines but could prevent HIV infection, as well as fresh prevention concepts that expand beyond the most established tools. The FOA also highlights innovation in how these prevention strategies are delivered, recognizing that real-world impact depends not only on what the prevention product is, but also on whether it can be used consistently, safely, and acceptably. Delivery strategy research can include approaches that improve adherence, optimize dosing schedules, or enable sustained or targeted delivery in ways that better match user needs and real-life settings.
Another key focus area is studying how nBP prevention strategies affect mucosal function in the genital and gastrointestinal (GI) tracts. Because HIV transmission commonly involves mucosal surfaces, understanding how prevention products interact with and influence mucosal biology is essential. This includes evaluating safety and biological impact on tissues and immune function in these sites, as well as assessing whether prevention candidates alter susceptibility factors, inflammation, epithelial integrity, or the local environment in ways that could influence HIV risk. This line of work is important both for minimizing unintended harm and for optimizing prevention efficacy by ensuring that interventions support, rather than compromise, protective mucosal defenses.
The announcement also explicitly supports emerging technologies that enable or improve major categories of HIV prevention interventions such as microbicides, pre-exposure prophylaxis (PrEP), and Multipurpose Prevention Technologies (MPT). Microbicides broadly refer to products intended to reduce the risk of HIV infection when applied to mucosal surfaces, while PrEP refers to biomedical approaches (often drug-based) used by HIV-negative individuals to prevent infection before exposure. MPTs are designed to address multiple sexual and reproductive health needs at once, such as preventing HIV alongside other sexually transmitted infections and/or unintended pregnancy. By calling out enabling technologies, PIP signals interest in platforms, systems, or methods that could make these prevention approaches more effective, easier to use, or more feasible to deploy at scale.
From an administrative standpoint, this is a discretionary grant opportunity under NIH, tied to CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The funding opportunity number is RFA-AI-13-059, posted February 20, 2014, with an original and current closing date of July 10, 2014, and an archive date of August 10, 2014. The estimated total funding amount listed is $2,400,000, and the award ceiling is $400,000, indicating that individual awards were expected not to exceed that upper limit (typically referring to direct costs per year, unless otherwise specified in the full FOA). There is no cost sharing or matching requirement, which means applicants are not required to commit non-federal matching funds as a condition of receiving an award.
Eligibility is broad and includes many types of domestic and international organizations. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public housing authorities/Indian housing authorities; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The FOA also makes clear that a wide range of special categories are eligible, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations and eligible federal agencies. Importantly, non-U.S. entities (foreign organizations and foreign institutions) are eligible to apply, non-U.S. components of U.S. organizations are eligible, and foreign components as defined by NIH policy are allowed, which opens participation to international research teams and global collaborations where scientifically justified.
For applicants or institutions needing the official details, the FOA is available through NIH at the provided link (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-059.html). The contact listed for access or linking issues is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs): Prevention Innovation Program (PIP) (R01) - RFA-AI-13-059
What is the Prevention Innovation Program (PIP) (R01)?
The Prevention Innovation Program (PIP) (R01) is an NIH funding opportunity focused on advancing non-vaccine biomedical prevention (nBP) research intended to reduce or prevent HIV acquisition and transmission. It is designed to strengthen and sustain the long-term pipeline of HIV prevention options by supporting projects that could meaningfully move the field forward if successful.
What does "non-vaccine biomedical prevention (nBP)" mean in this program?
In this opportunity, nBP refers to HIV prevention strategies that are biomedical in nature but are not vaccines. Examples referenced in the announcement include approaches related to microbicides, pre-exposure prophylaxis (PrEP), and Multipurpose Prevention Technologies (MPT), along with enabling technologies that improve these categories.
What type of NIH grant mechanism is used for this opportunity?
This funding opportunity uses the NIH Research Project Grant (R01) mechanism, which generally supports hypothesis-driven or milestone-driven research and development efforts with enough scope to move a prevention concept forward through key stages of discovery and early development.
What is the main goal or emphasis of PIP?
A major emphasis is on discovering and developing novel or underexplored nBP candidates and strategies for HIV prevention, particularly those that are high-risk and highly innovative and may not yet have extensive supporting data.
What does the program mean by "high-risk" and "highly innovative" research?
Based on the description provided, PIP encourages proposals that pursue newer concepts, less-tested approaches, or underexplored candidates. The intent is to allow scientifically promising ideas to be explored even if they do not yet have extensive preliminary data, as long as they could substantially advance HIV prevention if successful.
What kinds of projects are encouraged under this FOA?
The opportunity highlights projects that discover and develop novel or underexplored non-vaccine HIV prevention agents, formulations, or biological approaches. It also supports research that improves how prevention strategies are delivered so they can be used consistently, safely, and acceptably in real-world settings.
Does PIP support research on delivery strategies for HIV prevention tools?
Yes. The FOA specifically recognizes that real-world impact depends on delivery and use, not only on the prevention product itself. Delivery strategy research may include approaches that improve adherence, optimize dosing schedules, or enable sustained or targeted delivery that better matches user needs and real-life settings.
Why does the FOA focus on mucosal function in the genital and gastrointestinal (GI) tracts?
Because HIV transmission commonly involves mucosal surfaces, the FOA emphasizes understanding how prevention products interact with mucosal biology in the genital and GI tracts. This includes evaluating safety and biological impact on tissues and immune function, as well as whether candidates affect susceptibility factors, inflammation, epithelial integrity, or the local environment in ways that could influence HIV risk.
What kinds of mucosal biology questions does the program call out?
The description notes interest in evaluating safety and biological impact on mucosal tissues and immune function, and assessing whether prevention candidates alter factors such as inflammation, epithelial integrity, susceptibility, or the local mucosal environment in ways that could affect HIV risk.
Does the FOA support enabling technologies for established prevention categories?
Yes. The announcement explicitly supports emerging technologies that enable or improve major categories of HIV prevention interventions, including microbicides, PrEP, and Multipurpose Prevention Technologies (MPT).
What are microbicides in the context of this program?
Microbicides are described as products intended to reduce the risk of HIV infection when applied to mucosal surfaces.
What is PrEP in the context of this program?
PrEP (pre-exposure prophylaxis) is described as a biomedical prevention approach, often drug-based, used by HIV-negative individuals to prevent infection before exposure.
What are Multipurpose Prevention Technologies (MPT) as described here?
MPTs are described as technologies designed to address multiple sexual and reproductive health needs at once, such as preventing HIV alongside other sexually transmitted infections and/or unintended pregnancy.
What is the funding opportunity number for this program?
The funding opportunity number is RFA-AI-13-059.
Which NIH institute or program area is associated with the FOA based on the information provided?
The opportunity is described as an NIH program and is tied to CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
What are the CFDA numbers associated with this opportunity?
The CFDA numbers listed are 93.855 and 93.856.
What is the estimated total funding amount listed for this opportunity?
The estimated total funding amount listed is $2,400,000.
What is the award ceiling for individual awards?
The award ceiling is $400,000, meaning individual awards were expected not to exceed that upper limit (typically referring to direct costs per year, unless otherwise specified in the full FOA).
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement, meaning applicants are not required to commit non-federal matching funds as a condition of receiving an award.
When was the FOA posted, and what are the key dates listed?
The FOA was posted February 20, 2014. The original and current closing date listed is July 10, 2014, and the archive date is August 10, 2014.
Is this opportunity still open?
Based on the dates provided, the closing date is July 10, 2014, and the FOA has an archive date of August 10, 2014, indicating it is not currently open.
What kinds of organizations are eligible to apply?
Eligibility is described as broad and includes domestic and international organizations. Eligible applicants include various levels of government (state, county, city/township, and special district), independent school districts, public housing authorities/Indian housing authorities, public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with or without 501(c)(3) status (other than institutions of higher education), for-profit organizations other than small businesses, and small businesses.
Are nonprofits eligible even if they do not have 501(c)(3) status?
Yes. The eligibility list includes nonprofits with or without 501(c)(3) status (other than institutions of higher education).
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are listed as eligible, and small businesses are also listed as eligible.
Are international (non-U.S.) organizations eligible to apply?
Yes. The FOA states that non-U.S. entities (foreign organizations and foreign institutions) are eligible to apply.
Are non-U.S. components of U.S. organizations allowed?
Yes. The information provided states that non-U.S. components of U.S. organizations are eligible.
Are foreign components allowed under NIH policy?
Yes. The description indicates that foreign components, as defined by NIH policy, are allowed.
Are minority-serving institutions and special organizational categories eligible?
Yes. The eligibility description explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), and also notes faith-based or community-based organizations and eligible federal agencies.
Where can applicants find the official FOA details?
The FOA is available through NIH at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-059.html
Who is listed as the contact for access or linking issues?
The contact listed for access or linking issues is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What is the stated purpose of supporting a long-term pipeline of HIV prevention options?
The program is positioned to strengthen and sustain long-term HIV prevention innovation by encouraging high-risk, highly innovative projects that can explore new concepts or candidates, with the goal of expanding future prevention options.
Browse more opportunities from the same category: Health
Next opportunity: 2014 2015 GDA APS
Previous opportunity: Preservation Assistance Grants for Smaller Institutions
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 13 059
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 13 059) also looked into and applied for these:
| Funding Opportunity |
|---|
| National Center of Excellence for the Prevention of Childhood Agricultural Injury Apply for RFA OH 14 005 Funding Number: RFA OH 14 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,200,000 |
| Supporting Improved Health for all People in the Kingdom of Cambodia by Strengthening the Ministry of Healths Capacity to Lead Disease Prevention and Control Efforts and Develop Sustainable Health Delivery Systems under the Presidents Emergency Plan Apply for CDC RFA GH12 122603CONT14 Funding Number: CDC RFA GH12 122603CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| First in Human and Early Stage Clinical Trials of Novel Investigational Drugs for Psychiatric Disorders (U01) Apply for PAR 14 107 Funding Number: PAR 14 107 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R21/R33) Apply for RFA MH 15 300 Funding Number: RFA MH 15 300 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R33) Apply for RFA MH 15 310 Funding Number: RFA MH 15 310 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Effectiveness Studies and Services Research Grants (R34) Apply for RFA MH 15 330 Funding Number: RFA MH 15 330 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Affordable Care Act State Loan Repayment Program (SLRP) Apply for HRSA 14 033 Funding Number: HRSA 14 033 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Improving the Impact of Laboratory Practice A New Paradigm for Metrics, CSELS and DLPSS Apply for CDC RFA OE13 130402CONT14 Funding Number: CDC RFA OE13 130402CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Health Promotion and Disease Prevention Research Centers Special Interest Project Competitive Supplements (SIPs) Apply for RFA DP 14 0010101SUPP14 Funding Number: RFA DP 14 0010101SUPP14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Research Approaches to Improve the Care and Outcomes of Apply for RFA DD 14 002 Funding Number: RFA DD 14 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Silvio O. Conte Centers for Basic or Translational Mental Health Research (P50) Apply for PAR 14 120 Funding Number: PAR 14 120 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Consortium for Food Allergy Research (U19) Apply for RFA AI 14 003 Funding Number: RFA AI 14 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Health Impact Assessment for Improved Community Design Apply for CDC RFA EH14 1407 Funding Number: CDC RFA EH14 1407 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $145,000 |
| Strengthening the National Institutes of Health in the Republic of Mozambique under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 115804CONT14 Funding Number: CDC RFA GH11 115804CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Strengthening Human Resources for Health through Continuing Education of Health Workers in the Federal Democratic Republic of Ethiopia under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 116704CONT14 Funding Number: CDC RFA GH11 116704CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Demographic Surveillance Study support in the Republic of Mozambique under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1110104CONT14 Funding Number: CDC RFA GH11 1110104CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Surveillance and Research of Muscular Dystrophies and Neuromuscular Disorders Apply for RFA DD 14 001 Funding Number: RFA DD 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Increasing the Capacity of the Government of Barbados to expand Coordinated HIV Prevention, Strategic Information, and Laboratory Programs under the Presidents Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 120403CONT14 Funding Number: CDC RFA GH12 120403CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Initiative for Maximizing Student Development (IMSD) (R25) Apply for PAR 14 121 Funding Number: PAR 14 121 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Health Surveillance through Networking, Regional Coordination and Strengthening of Technology, Communication and Training in Epidemiology to Improve Emergency Response in Publich Health under the International Health Regulations and the Hea Apply for CDC RFA GH10 100505CONT14 Funding Number: CDC RFA GH10 100505CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 13 059", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.